Mehrshad Vafaie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mehrshad Vafaie has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Moritz Biener
Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany
8 shared publicationsEvangelos Giannitsis
6 shared publicationsMatthias Mueller
6 shared publications- Evangelos Giannitsis
Department of Cardiology, Pulmonology and Angiology, University Hospital Heidelberg, Heidelberg, Germany
5 shared publications Hugo A. Katus
Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Germany
4 shared publicationsHugo A Katus
3 shared publications
Latest Publications
- Open Access
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction
Background/Introduction: MicroRNAs (miRNAs) are promising biomarkers due to their high specificity and may facilitate differential diagnosis of patients presenting with suspected acute coronary syndrome (ACS) to the emergency department (ED). Purpose: To assess the diagnostic value of eleven miRNAs for the detection of non-ST-segment elevation myocardial infarction (NSTEMI). Methods: 1,042 patients presenting between August 2014 and April 2017 to the ED with suspected ACS were included. NSTEMI was diagnosed per criteria of the 4th Universal definition of myocardial infarction (UDMI) using high-sensitivity troponin T (hs-cTnT). Expression levels of eleven microRNAs (miR-21, miR-22, miR-29a, miR-92a, miR-122, miR-126, miR-132, miR-133, miR-134, miR-191, miR-423) were determined using RT-qPCR. Discrimination of NSTEMI was assessed for individual and a panel of miRNAs compared to the hs-cTnT reference using C-statistics and reclassification analysis. Results: NSTEMI was diagnosed in 137 (13.1%) patients. The AUC of the hs-cTnT based reference was 0.937. In a multivariate model three miRNAs (miR-122, miR-133 and miR-134) were found to be associated with NSTEMI with AUCs between 0.506 and 0.656. A panel consisting of these miRNAs revealed an AUC of 0.662 for the diagnosis of NSTEMI. The AUC of the combination of the miRNA panel and troponin reference was significantly lower than the reference standard (AUC: 0.897 vs. 0.937, p=0.006). Despite a significant improvement of NSTEMI reclassification measured by IDI and NRI, miRNAs did not improve specificity of hs-cTnT kinetic changes for the diagnosis of NSTEMI (ΔAUC: 0.04). Conclusion: Although single miRNAs are significantly associated with the diagnosis of NSTEMI a miRNA panel does not add diagnostic accuracy to the hs-cTnT reference considering baseline values and kinetic changes as recommended by 4th version of UDMI. Funding Acknowledgement: Type of funding sources: Foundation. Main funding source(s): German Heart Foundation/German Foundation of Heart Research.CIBERES (CB07/06/2008 to DdGC) is a project from Carlos III Health Institute. Central illustration
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Open AccessDiagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction
Background/Introduction: MicroRNAs (miRNAs) are promising biomarkers due to their high specificity and may facilitate differential diagnosis of patients presenting with suspected acute coronary syndrome (ACS) to the emergency department (ED). Purpose: To assess the diagnostic value of eleven miRNAs for the detection of non-ST-segment elevation myocardial infarction (NSTEMI). Methods: 1,042 patients presenting between August 2014 and April 2017 to the ED with suspected ACS were included. NSTEMI was diagnosed per criteria of the 4th Universal definition of myocardial infarction (UDMI) using high-sensitivity troponin T (hs-cTnT). Expression levels of eleven microRNAs (miR-21, miR-22, miR-29a, miR-92a, miR-122, miR-126, miR-132, miR-133, miR-134, miR-191, miR-423) were determined using RT-qPCR. Discrimination of NSTEMI was assessed for individual and a panel of miRNAs compared to the hs-cTnT reference using C-statistics and reclassification analysis. Results: NSTEMI was diagnosed in 137 (13.1%) patients. The AUC of the hs-cTnT based reference was 0.937. In a multivariate model three miRNAs (miR-122, miR-133 and miR-134) were found to be associated with NSTEMI with AUCs between 0.506 and 0.656. A panel consisting of these miRNAs revealed an AUC of 0.662 for the diagnosis of NSTEMI. The AUC of the combination of the miRNA panel and troponin reference was significantly lower than the reference standard (AUC: 0.897 vs. 0.937, p=0.006). Despite a significant improvement of NSTEMI reclassification measured by IDI and NRI, miRNAs did not improve specificity of hs-cTnT kinetic changes for the diagnosis of NSTEMI (ΔAUC: 0.04). Conclusion: Although single miRNAs are significantly associated with the diagnosis of NSTEMI a miRNA panel does not add diagnostic accuracy to the hs-cTnT reference considering baseline values and kinetic changes as recommended by 4th version of UDMI. Funding Acknowledgement: Type of funding sources: Foundation. Main funding source(s): German Heart Foundation/German Foundation of Heart Research.CIBERES (CB07/06/2008 to DdGC) is a project from Carlos III Health Institute. Central illustration
- 10 May 2019
- Published by Springer Nature in Die Innere Medizin
- Vol. 60 (6) , 555-563
Kardiales Troponin und mehr beim akuten Koronarsyndrom
Kardiale Biomarker sind essenzieller Bestandteil der Diagnostik des akuten Koronarsyndroms (ACS). Kardiales Troponin (cTn) ist der sensitivste diagnostische Biomarker beim ACS und erlaubt die Abgrenzung des akuten Nicht-ST-Strecken-Hebungs-Infarkts (NSTEMI) von der instabilen Angina. Bei der Abklärung akuter Thoraxschmerzen müssen sämtliche kardialen und nichtkardialen Differenzialdiagnosen berücksichtigt werden. Neben dem ACS hat cTn auch bei einer Vielzahl anderer Krankheitsbilder eine prognostische Bedeutung. Bevorzugt sollten hochsensitive cTn(hsTn)-Assays eingesetzt werden. Mit Point-of-care(POC)-Troponintests ist in der Regel ein Nachweis („rule-in“), jedoch kein zuverlässiger Ausschluss („rule-out“) des akuten Myokardinfarkts (MI) möglich, da die meisten POC-cTn-Assays über keine ausreichende diagnostische Sensitivität verfügen. Neuere Assays könnten diese Limitation überwinden. Für den Ausschluss des MI mit hsTn-Assays existieren diverse Protokolle. Bei Verwendung von hsTn-Assays kann je nach Protokoll bereits bei Aufnahme mit oder ohne zusätzlicher Bestimmung von Copeptin nach 1, 2 oder 3 h ein MI ausgeschlossen werden. In diesem Beitrag werden Protokolle und Leitlinienempfehlungen zur Infarktdiagnostik dargestellt. Dabei wird im Besonderen auf die Rolle von POC-Troponinassays eingegangen. Cardiac biomarkers are an integral component of the diagnostic work-up of patients with suspected acute coronary syndrome (ACS). Cardiac troponin (cTn) is the most sensitive diagnostic biomarker for patients with ACS and enables the differentiation of acute non-ST-elevation myocardial infarction (NSTEMI) from unstable angina. All cardiac and non-cardiac differential diagnoses must be taken into consideration. The use of cTn has a prognostic value in a multitude of acute and chronic diseases apart from ACS. Highly sensitive cTn (hsTn) assays should be preferentially used. Point-of-care (POC) troponin assays can be used for rule-in of acute MI but are generally not useful for rule-out of MI due to their lack of sensitivity compared to hsTn assays. This, however, may change with recent developments of newer and improved POC troponin assays. For exclusion of MI using hsTn assays, there are various protocols available, such as the instant rule-out with undetectable hsTn levels at admission or normal hsTn/cTn levels combined with normal copeptin levels or rule-out with serial controls of hsTn after 1, 2 or 3 h. This article provides an overview of guideline-recommended rule-out protocols for patients with suspected ACS and discusses recent advances in POC troponin assays.
- 10 May 2019
- Published by Springer Nature in Die Innere Medizin
- Vol. 60 (6) , 555-563
Kardiales Troponin und mehr beim akuten Koronarsyndrom
Kardiale Biomarker sind essenzieller Bestandteil der Diagnostik des akuten Koronarsyndroms (ACS). Kardiales Troponin (cTn) ist der sensitivste diagnostische Biomarker beim ACS und erlaubt die Abgrenzung des akuten Nicht-ST-Strecken-Hebungs-Infarkts (NSTEMI) von der instabilen Angina. Bei der Abklärung akuter Thoraxschmerzen müssen sämtliche kardialen und nichtkardialen Differenzialdiagnosen berücksichtigt werden. Neben dem ACS hat cTn auch bei einer Vielzahl anderer Krankheitsbilder eine prognostische Bedeutung. Bevorzugt sollten hochsensitive cTn(hsTn)-Assays eingesetzt werden. Mit Point-of-care(POC)-Troponintests ist in der Regel ein Nachweis („rule-in“), jedoch kein zuverlässiger Ausschluss („rule-out“) des akuten Myokardinfarkts (MI) möglich, da die meisten POC-cTn-Assays über keine ausreichende diagnostische Sensitivität verfügen. Neuere Assays könnten diese Limitation überwinden. Für den Ausschluss des MI mit hsTn-Assays existieren diverse Protokolle. Bei Verwendung von hsTn-Assays kann je nach Protokoll bereits bei Aufnahme mit oder ohne zusätzlicher Bestimmung von Copeptin nach 1, 2 oder 3 h ein MI ausgeschlossen werden. In diesem Beitrag werden Protokolle und Leitlinienempfehlungen zur Infarktdiagnostik dargestellt. Dabei wird im Besonderen auf die Rolle von POC-Troponinassays eingegangen. Cardiac biomarkers are an integral component of the diagnostic work-up of patients with suspected acute coronary syndrome (ACS). Cardiac troponin (cTn) is the most sensitive diagnostic biomarker for patients with ACS and enables the differentiation of acute non-ST-elevation myocardial infarction (NSTEMI) from unstable angina. All cardiac and non-cardiac differential diagnoses must be taken into consideration. The use of cTn has a prognostic value in a multitude of acute and chronic diseases apart from ACS. Highly sensitive cTn (hsTn) assays should be preferentially used. Point-of-care (POC) troponin assays can be used for rule-in of acute MI but are generally not useful for rule-out of MI due to their lack of sensitivity compared to hsTn assays. This, however, may change with recent developments of newer and improved POC troponin assays. For exclusion of MI using hsTn assays, there are various protocols available, such as the instant rule-out with undetectable hsTn levels at admission or normal hsTn/cTn levels combined with normal copeptin levels or rule-out with serial controls of hsTn after 1, 2 or 3 h. This article provides an overview of guideline-recommended rule-out protocols for patients with suspected ACS and discusses recent advances in POC troponin assays.
- 15 June 2013
Cardiac Troponin T.
Cardiac troponins (cTns) T and I are exclusively expressed at high concentrations in cardiac muscle and have emerged as the preferred biomarker in the universal definition of myocardial infarction (MI). With the recent introduction of high-sensitivity (hs) assays, diagnostic sensitivity for earlier detection of MI has substantially improved. However, lowering the diagnostic cut-off has increased the detection of myocardial injuries in various non-acute coronary syndrome (ACS) conditions, which are not related to myocardial ischemia, leading to rising difficulties in diagnosing MI in clinical situations. Several approaches, such as serial sampling and incorporation of relative or absolute δ-changes, have been proposed to overcome the limitation of decreased sensitivity for MI diagnosis with hs-cTn assays. Current consensus for rapid rule-in proposes a 20% increase within 3 or 6h when baseline cTn levels are elevated. In the case of negative baseline values, relative increases ≥50% above the 99th percentile were found to be adequate to improve accuracy of MI diagnosis. Besides improved diagnostic accuracy for myocardial injury, even minor cTn elevations provide important prognostic information, and increased levels of cTn are associated with adverse outcomes in both the ACS and non-ACS condition, irrespective of whether the underlying cause is an acute or chronic illness. Thus, it is highly likely that lowering the diagnostic cut-off with even more sensitive assays might improve risk stratification in both conditions.
- 15 June 2013
Cardiac Troponin T.
Cardiac troponins (cTns) T and I are exclusively expressed at high concentrations in cardiac muscle and have emerged as the preferred biomarker in the universal definition of myocardial infarction (MI). With the recent introduction of high-sensitivity (hs) assays, diagnostic sensitivity for earlier detection of MI has substantially improved. However, lowering the diagnostic cut-off has increased the detection of myocardial injuries in various non-acute coronary syndrome (ACS) conditions, which are not related to myocardial ischemia, leading to rising difficulties in diagnosing MI in clinical situations. Several approaches, such as serial sampling and incorporation of relative or absolute δ-changes, have been proposed to overcome the limitation of decreased sensitivity for MI diagnosis with hs-cTn assays. Current consensus for rapid rule-in proposes a 20% increase within 3 or 6h when baseline cTn levels are elevated. In the case of negative baseline values, relative increases ≥50% above the 99th percentile were found to be adequate to improve accuracy of MI diagnosis. Besides improved diagnostic accuracy for myocardial injury, even minor cTn elevations provide important prognostic information, and increased levels of cTn are associated with adverse outcomes in both the ACS and non-ACS condition, irrespective of whether the underlying cause is an acute or chronic illness. Thus, it is highly likely that lowering the diagnostic cut-off with even more sensitive assays might improve risk stratification in both conditions.
Analytically false or true positive elevations of high sensitivity cardiac troponin: a systematic approach
CTnT or cTnI are routinely used in emergency units as the preferred biomarkers for the diagnosis of acute myocardial infarction (MI). According to joint criteria for the diagnosis of acute MI by the European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force, an acute MI should be diagnosed in patients with symptoms of myocardial ischaemia and detection of a rise and/or fall of cardiac biomarkers (preferentially troponins) with at least one value above the 99th percentile of the upper reference limit.1
Analytically false or true positive elevations of high sensitivity cardiac troponin: a systematic approach
CTnT or cTnI are routinely used in emergency units as the preferred biomarkers for the diagnosis of acute myocardial infarction (MI). According to joint criteria for the diagnosis of acute MI by the European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force, an acute MI should be diagnosed in patients with symptoms of myocardial ischaemia and detection of a rise and/or fall of cardiac biomarkers (preferentially troponins) with at least one value above the 99th percentile of the upper reference limit.1
- 1 November 2012
- Published by Elsevier in American Heart Journal
- Vol. 164 (5) , 698-705.e4
Effect of older age on diagnostic and prognostic performance of high-sensitivity troponin T in patients presenting to an emergency department
- 1 November 2012
- Published by Elsevier in American Heart Journal
- Vol. 164 (5) , 698-705.e4
Effect of older age on diagnostic and prognostic performance of high-sensitivity troponin T in patients presenting to an emergency department
- Open Access
- 1 January 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (1) , 209-218
Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary Syndrome
BACKGROUND: We evaluated kinetic changes of high-sensitivity cardiac troponin T (hs-cTnT) in patients with acute coronary syndrome (ACS) and patients with hs-cTnT increases not due to ACS to rule in or rule out non–ST-segment elevation myocardial infarction (STEMI). METHODS: hs-cTnT was measured serially in consecutive patients presenting to the emergency department. Patients with ACS who had at least 2 hs-cTnT measurements within 6 h and non-ACS patients with hs-cTnT concentrations above the 99th percentile value (14 ng/L) were enrolled to compare absolute and relative kinetic changes of hs-cTnT. RESULTS: For discrimination of non-STEMI (n = 165) in the entire study population (n = 784), the absolute δ change with the ROC-optimized value of 9.2 ng/L yielded an area under the curve of 0.898 and was superior to all relative δ changes (P < 0.0001). The positive predictive value for the absolute δ change was 48.7%, whereas the negative predictive value was 96.5%. In a specific ACS population with exclusion of STEMI (n = 342), the absolute δ change with the ROC-optimized value of 6.9 ng/L yielded a positive predictive value of 82.8% and a negative predictive value of 93.0%. In comparison to the ≥20% relative δ change, the ROC-optimized absolute δ change demonstrated a significantly added value for the entire study population and for the ACS cohort (net reclassification index 0.331 and 0.499, P < 0.0001). CONCLUSIONS: Absolute δ changes appear superior to relative δ changes in discriminating non-STEMI. A rise or fall of at least 9.2 ng/L in the entire study population and 6.9 ng/L in selected ACS patients seems adequate to rule-out non-STEMI. However, δ-values are useful to rule-in non-STEMI only in a specific ACS population.
- 1 January 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (1) , 209-218
Open AccessAbsolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary Syndrome
BACKGROUND: We evaluated kinetic changes of high-sensitivity cardiac troponin T (hs-cTnT) in patients with acute coronary syndrome (ACS) and patients with hs-cTnT increases not due to ACS to rule in or rule out non–ST-segment elevation myocardial infarction (STEMI). METHODS: hs-cTnT was measured serially in consecutive patients presenting to the emergency department. Patients with ACS who had at least 2 hs-cTnT measurements within 6 h and non-ACS patients with hs-cTnT concentrations above the 99th percentile value (14 ng/L) were enrolled to compare absolute and relative kinetic changes of hs-cTnT. RESULTS: For discrimination of non-STEMI (n = 165) in the entire study population (n = 784), the absolute δ change with the ROC-optimized value of 9.2 ng/L yielded an area under the curve of 0.898 and was superior to all relative δ changes (P < 0.0001). The positive predictive value for the absolute δ change was 48.7%, whereas the negative predictive value was 96.5%. In a specific ACS population with exclusion of STEMI (n = 342), the absolute δ change with the ROC-optimized value of 6.9 ng/L yielded a positive predictive value of 82.8% and a negative predictive value of 93.0%. In comparison to the ≥20% relative δ change, the ROC-optimized absolute δ change demonstrated a significantly added value for the entire study population and for the ACS cohort (net reclassification index 0.331 and 0.499, P < 0.0001). CONCLUSIONS: Absolute δ changes appear superior to relative δ changes in discriminating non-STEMI. A rise or fall of at least 9.2 ng/L in the entire study population and 6.9 ng/L in selected ACS patients seems adequate to rule-out non-STEMI. However, δ-values are useful to rule-in non-STEMI only in a specific ACS population.